Application No. 10/572,826 Response Dated: May 14, 2009

Reply to Restriction Requirement of April 24, 2009

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/572,826	First Named Inventor: LIU, Ziping
Filing Date (371 Date): 10/16/2006	Attorney Docket No.: 101193-1P US
Examiner: SHAMEEM, Golam M.	Group Art Unit: 1626
Customer No.: 22466	Confirmation No.: 3323
Title: Benzimidazole derivatives, compositions containing them, preparation thereof and	
uses thereof	

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO THE RESTRICTION REQUIREMENT

Sir:

The present Response is filed in regard to the Restriction Requirement dated April 8, 2009 in connection with the above-identified patent application.

In the Restriction Requirement, the Examiner restricted pending claims into five groups:

- Claims 1-4 and 10 drawn to a compound of formula I classified in classes 544,
 546 548 and numerous subclasses
- II. Claim 5 drawn to a subset of compound of formula I classified in classes 544, 546, 548 and numerous subclasses.
- III. Claims 8 and 9 drawn to a method for treatment of a disease classified in class 514 and several subclasses.
- IV. Claims 11 and 13-16 drawn to a method of use of a compound classified in class 514 and several subclasses.
- V. Claim 12 drawn to a method for preparing a compound of formula I classified in classes 544, 546,548 and several subclasses.

Applicants elect Group I, claims 1-4 and 10, without traverse.

The Examiner has further averred that the claims encompassed multiple species and were generic.

The Examiner requests Applicants to elect a species. Applicants hereby elect the compound represented by the following formula

Application No. 10/572,826 Response Dated: May 14, 2009

Reply to Restriction Requirement of April 24, 2009

, which is shown in Example 20 on pages 54-55 of the

specification.

Claims 1-4 and 10 of the elected Group encompass the elected species.

Although Applicants believe no additional fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 101193-1P US.

Respectfully submitted,
/Jianzhong SHEN, reg.#48076 /

Name: Jianzhong Shen
Dated: May 14, 2009
Reg. No.: 48076
Phone No.: 302-886-8854
Global Intellectual Property, Patents,

AstraZeneca, 1800 Concord Pike, Wilmington, DE-19850-5437